Therapeutic drug monitoring is becoming increasingly important in clinical decision-making in children with inflammatory bowel disease (IBD). However, enzyme-linked immunosorbent assay (ELISA) assays do not allow results to be provided in real-time. We sought to compare 2 point-of-care (POC) devices for quantification of serum infliximab concentration with 2 validated ELISA assays in children with IBD.
Determination of Serum Infliximab Concentration by Point-of-care Devices in Children with Inflammatory Bowel Disease / Curci, D.; Lucafo, M.; Cifu, A.; Bramuzzo, M.; Martelossi, S.; Favretto, D.; De Pellegrin, F.; Fabris, Martino; Vascotto, Fulvia; Naviglio, S.; Ventura, A.; Stocco, G.; Decorti, G.. - In: JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION. - ISSN 0277-2116. - STAMPA. - 69:4(2019), pp. 474-479. [10.1097/MPG.0000000000002410]
Determination of Serum Infliximab Concentration by Point-of-care Devices in Children with Inflammatory Bowel Disease
Curci D.;Lucafo M.;Bramuzzo M.;Favretto D.;FABRIS, MARTINO;VASCOTTO, FULVIA;Naviglio S.;Stocco G.;Decorti G.
2019-01-01
Abstract
Therapeutic drug monitoring is becoming increasingly important in clinical decision-making in children with inflammatory bowel disease (IBD). However, enzyme-linked immunosorbent assay (ELISA) assays do not allow results to be provided in real-time. We sought to compare 2 point-of-care (POC) devices for quantification of serum infliximab concentration with 2 validated ELISA assays in children with IBD.| File | Dimensione | Formato | |
|---|---|---|---|
|
curci.pdf
Accesso chiuso
Tipologia:
Documento in Versione Editoriale
Licenza:
Copyright Editore
Dimensione
220.95 kB
Formato
Adobe PDF
|
220.95 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
